|
|
|
|
|
Sponsored by: |
University of Leeds |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00389870 |
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cyclosporine may help irinotecan work better by making tumor cells more sensitive to the drug. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Panitumumab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether irinotecan is more effective when given with or without panitumumab or cyclosporine in treating colorectal cancer.
PURPOSE: This randomized phase III trial is studying irinotecan to compare how well it works when given with or without panitumumab or cyclosporine in treating patients with advanced or metastatic colorectal cancer that did not respond to fluorouracil.
Condition | Intervention | Phase |
Colorectal Cancer |
Drug: cyclosporine Drug: irinotecan hydrochloride Drug: panitumumab |
Phase III |
MedlinePlus related topics: | Cancer Colorectal Cancer |
ChemIDplus related topics: | Irinotecan Irinotecan hydrochloride Cyclosporine Cyclosporin Fluorouracil Panitumumab |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control |
Official Title: | A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in COLOrectal Cancer Therapy (PICCOLO)] |
Estimated Enrollment: | 1269 |
Study Start Date: | December 2006 |
Estimated Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are stratified according to prior cetuximab (yes vs no). Patients are randomized to 1 of 3 treatment arms.
In all arms, treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responding or stable disease may continue treatment in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and at 12 and 24 weeks.
After completion of study treatment, patients are followed every 12 weeks for 1 year.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: A total of 1,269 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of colorectal adenocarcinoma meeting 1 of the following criteria:
Disease progression during or after prior fluorouracil with or without oxaliplatin therapy and/or with or without bevacizumab
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
No ongoing requirement for cyclosporine or any other medication including, but not limited to, the following:
United Kingdom, England | |||||
Addenbrooke's Hospital | Recruiting | ||||
Cambridge, England, United Kingdom, CB2 2QQ | |||||
Contact: Charles B. Wilson, MD 44-1223-217-110 charles.wilson@addenbrookes.nhs.uk | |||||
Airedale General Hospital | Recruiting | ||||
Keighley, England, United Kingdom, BD20 6TD | |||||
Contact: S. Michael Crawford, MD 44-1535-652-511 michael.crawford@anhst.nhs.uk | |||||
Bristol Haematology and Oncology Centre | Recruiting | ||||
Bristol, England, United Kingdom, BS2 8ED | |||||
Contact: Stephen J. Falk, MD 44-117-928-2416 stephen.falk@ubht.nhs.uk | |||||
Cancer Research Centre at Weston Park Hospital | Recruiting | ||||
Sheffield, England, United Kingdom, S1O 2SJ | |||||
Contact: Jonathan Wadsley 44-114-226-5000 | |||||
Cheltenham General Hospital | Recruiting | ||||
Cheltenham, England, United Kingdom, GL53 7AN | |||||
Contact: Kim Benstead, MD 44-845-422-2222 kim.benstead@egnhst.org.uk | |||||
Clatterbridge Centre for Oncology | Recruiting | ||||
Merseyside, England, United Kingdom, CH63 4JY | |||||
Contact: Sun Myint, MD, FRCP(Edin), DMRT, FFRCS, F 44-151-334-1155 sun.myint@ccotrust.nhs.uk | |||||
Cookridge Hospital | Recruiting | ||||
Leeds, England, United Kingdom, LS16 6QB | |||||
Contact: Matthew T. Seymour, MA, MD, FRCP 44-113-267-3411 | |||||
Eastbourne District General Hospital | Recruiting | ||||
Eastbourne, England, United Kingdom, BN21 2UD | |||||
Contact: Fiona McKinna, MD 44-132-341-7400 fiona.mckinna@bsuh.nhs.uk | |||||
Poole Hospital NHS Trust | Recruiting | ||||
Poole Dorset, England, United Kingdom, BH15 2JB | |||||
Contact: Tamas Hickish, MD 44-120-266-5511 | |||||
Hinchingbrooke Hospital | Recruiting | ||||
Huntingdon, England, United Kingdom, PE18 6NT | |||||
Contact: Li Tee Tan, MD 44-1480-416-416 | |||||
Huddersfield Royal Infirmary | Recruiting | ||||
Huddersfield, West Yorks, England, United Kingdom, HD3 3EA | |||||
Contact: Jo Dent 44-1484-342-000 | |||||
James Cook University Hospital | Recruiting | ||||
Middlesbrough, England, United Kingdom, TS4 3BW | |||||
Contact: N. Wadd, MD 44-1642-850-850 | |||||
Mid Kent Oncology Centre at Maidstone Hospital | Recruiting | ||||
Maidstone, England, United Kingdom, ME16 9QQ | |||||
Contact: Mark Hill, MD 44-1622-729-000 | |||||
Mount Vernon Cancer Centre at Mount Vernon Hospital | Recruiting | ||||
Northwood, England, United Kingdom, HA6 2RN | |||||
Contact: Robert Glynne-Jones, MD 44-192-382-6111 robglynnejones@nhs.net | |||||
Peterborough Hospitals Trust | Recruiting | ||||
Peterborough, England, United Kingdom, PE3 6DA | |||||
Contact: Karen E. McAdam, MD 44-173-387-4000 | |||||
Great Western Hospital | Recruiting | ||||
Swindon, England, United Kingdom, SN3 6BB | |||||
Contact: Claire Blesing 44-1793-604-020 | |||||
Portsmouth Oncology Centre at Saint Mary's Hospital | Recruiting | ||||
Portsmouth Hants, England, United Kingdom, PO3 6AD | |||||
Contact: Ann O'Callaghan, MD 44-23-9228-6000 ext. 2361 ann.o'callaghan@porthosp.nhs.uk | |||||
Queen Elizabeth Hospital - Woolwich | Recruiting | ||||
London, England, United Kingdom, SE18 4QH | |||||
Contact: Nick Maisey 44-208-836-6000 nick.maisey@kcl.ac.uk | |||||
Royal Bournemouth Hospital NHS Trust | Recruiting | ||||
Bournemouth, England, United Kingdom, BH7 7DW | |||||
Contact: Tamas Hickish, MD 44-120-230-3626 tamas.hickish@rbch.nhs.uk | |||||
Royal Liverpool University Hospital | Recruiting | ||||
Liverpool, England, United Kingdom, L7 8XP | |||||
Contact: David Smith, MD 44-151-706-2000 | |||||
Royal Marsden - Surrey | Recruiting | ||||
Sutton, England, United Kingdom, SM2 5PT | |||||
Contact: Ian Chau, MD 44-208-661-3582 | |||||
Sussex Cancer Centre at Royal Sussex County Hospital | Recruiting | ||||
Brighton, England, United Kingdom, BN2 5BE | |||||
Contact: Andrew Webb, MD 44-12-7369-6955 | |||||
St. Luke's Cancer Centre at Royal Surrey County Hospital | Recruiting | ||||
Guildford, England, United Kingdom, GU2 7XX | |||||
Contact: Gary W. Middleton 44-148-357-1122 gmiddleton@royalsurrey.nhs.uk | |||||
St. Mary's Hospital | Recruiting | ||||
London, England, United Kingdom, W2 1NY | |||||
Contact: Susan Cleator, MD, PhD 44-207-886-6666 s.cleator@imperial.ac.uk | |||||
South Tyneside District Hospital | Recruiting | ||||
South Shields, England, United Kingdom, NE34 0PL | |||||
Contact: Ashraf Azzabi, MD 44-191-202-4178 | |||||
UCL Cancer Institute | Recruiting | ||||
London, England, United Kingdom, NW3 2PF | |||||
Contact: Astrid Mayer, MD 44-207-794-0500 a.mayer@ucl.ac.uk | |||||
Worthing Hospital | Recruiting | ||||
Worthing, England, United Kingdom, BN11 2DH | |||||
Contact: Andrew Webb, MD 44-1903-205-111 | |||||
Yeovil District Hospital | Recruiting | ||||
Yeovil, England, United Kingdom, BA21 4AT | |||||
Contact: Stephen J. Falk, MD 44-193-547-5122 stephen.falk@swest.uhs.uk | |||||
United Kingdom, Scotland | |||||
Edinburgh Cancer Centre at Western General Hospital | Recruiting | ||||
Edinburgh, Scotland, United Kingdom, EH4 2XU | |||||
Contact: Lesley Dawson 44-131-537-1000 | |||||
United Kingdom, Wales | |||||
Ysbyty Gwynedd | Recruiting | ||||
Bangor, Wales, United Kingdom, LL57 2PW | |||||
Contact: Catherine Bale 44-124-838-4384 | |||||
South West Wales Cancer Institute | Recruiting | ||||
Swansea, Wales, United Kingdom, SA2 8QA | |||||
Contact: John Wagstaff, MD, MB, ChB, FRCP 44-179-220-2666 profwagstaff@netscape.net | |||||
Velindre Cancer Center at Velindre Hospital | Recruiting | ||||
Cardiff, Wales, United Kingdom, CF14 2TL | |||||
Contact: Timothy Maughan, MD 44-29-2061-5888 | |||||
Glan Clwyd Hospital | Recruiting | ||||
Rhyl, Denbighshire, Wales, United Kingdom, LL 18 5UJ | |||||
Contact: Simon Gollins, MD 44-1745-583-910 simon.gollins@cd-tr.wales.nhs.uk |
University of Leeds |
Study Chair: | Matthew T. Seymour, MA, MD, FRCP | Cookridge Hospital |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000510284, CTRU-PICCOLO-MO-05-7289, EUDRACT-2005-003492-20, CTAAC-CTRU-PICCOLO-MO-05-7289, AMGEN-CTRU-PICCOLO-MO-05-7289, EU-20647 |
First Received: | October 18, 2006 |
Last Updated: | August 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00389870 |
Health Authority: | Unspecified |
|
|
|
|
|
|